
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934**

For the month of June 2022

Commission File Number 001-38367

SOL-GEL TECHNOLOGIES LTD.

(Translation of registrant's name into English)

7 Golda Meir Street

Ness Ziona 7403650, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Sol-Gel Technologies Ltd. (the “Company”) has made available an updated presentation about its business, a copy of which is furnished herewith as Exhibit 99.1 and incorporated by reference.

[Exhibit 99.1: Corporate Presentation.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOL-GEL TECHNOLOGIES LTD.

Date: June 7, 2022

By: /s/ Gilad Mamlok
Gilad Mamlok
Chief Financial Officer



NASDAQ: SLGL

FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the timing of future clinical trials, our expected cash runway, and the benefits we expect to receive under our agreement with Galderma. These forward-looking statements include information about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management's current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the risk that we will not receive all of the anticipated benefits under our agreement with Galderma, the risk that TWYNEO and/or EPSOLAY will not provide treatment to the number of patients anticipated or will otherwise not be commercially successful, risks relating to the effects of COVID 19 (coronavirus) as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, Europe or Israel; and (xv) loss or retirement of key executives and research scientists. These and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on April 4, 2022, as amended, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Except as required by law, we undertake no obligation to update any forward-looking statements in this presentation.

PIONEERING TOPICAL DERMATOLOGICAL DRUGS

Two FDA Approvals Within One Year



Not a real patient



Not a real patient

TWYNEO® FOR ACNE WAS LAUNCHED

First and only FDA Approved Fixed-Dose Combination of Tretinoin and Benzoyl Peroxide



*Say hello to this
never-before-seen
combo*

TWYNEO® FOR ACNE WAS LAUNCHED

Remarkably Growing Sales



TWYNEO® OFFERS COMPREHENSIVE TREATMENT FOR ACNE PATIENTS

Potential to Become 1st Line Treatment

- Acne vulgaris is a multifactorial disease. Even though benzoyl peroxide and tretinoin are widely prescribed separately and have a complementary mechanism of action, so far, they could not be applied concomitantly because benzoyl peroxide decomposes tretinoin
- TWYNEO contains a fixed-dose combination of tretinoin and benzoyl peroxide. TWYNEO uses Sol-Gel's patented technology to prevent tretinoin from being degraded by benzoyl peroxide and slowly releases each of the active drug ingredients over time to provide a favorable efficacy and safety profile
- TWYNEO is protected by granted patents until 2038 and by a pending patent application until 2041



Not a real patient

TREATING SEVERE ACNE PATIENT WITH TWYNEO®

Subject 507-003 || 18 Years Old | Female | White | Not Hispanic or Latino*

BASELINE



"Severe"; 29 inflamed lesions
31 non-inflamed lesions; 1 nodule

WEEK 12



"Moderate"; 9 inflamed lesions
5 non-inflamed lesions; No nodules



* Individual results vary

Company and Products Overview | June 2022 7

EPSOLAY® FOR INFLAMMATORY LESIONS OF ROSACEA WAS APPROVED

First and only Benzoyl Peroxide in Rosacea

Rosacea care with the brilliant
touch of technology



EPSOLAY® OFFERS EFFECTIVE TOPICAL TREATMENT FOR ROSACEA PATIENTS

Potential to Change Treatment Landscape

- Inflammatory lesions of rosacea resemble acne vulgaris, except that comedones (whiteheads and blackheads) are absent and only inflammatory lesions exist
- EPSOLAY contains encapsulated benzoyl peroxide, using Sol-Gel's patented technology. Benzoyl peroxide is an effective antibacterial drug that is not associated with bacterial resistance and is used to treat acne but not rosacea as it is assumed that rosacea patients cannot tolerate benzoyl peroxide. In Phase III clinical studies, EPSOLAY demonstrated statistically significant higher efficacy than the vehicle and favorable safety and tolerability profile, similar to vehicle
- EPSOLAY is protected by granted patents until 2040 and by a pending patent application until 2041



Not a real patient

TREATING SEVERE ROSACEA PATIENT WITH EPSOLAY®

Subject 116-009 || 41 Years Old | Female | White | Not Hispanic or Latino*



* Individual results vary

PARTNERING WITH MARKET LEADER GALDERMA

Galderma has Heritage of Successful Drugs in Acne and Rosacea

DIFFERIN®

Epiduo™



AKLIEF®
(trifarotene)
Cream, 0.005%



ONCE-DAILY

soolantra®
(IVERMECTIN) CREAM, 1%



MIRVASO®
(brimonidine) topical gel, 0.33%

Once-daily 40 mg Capsules

ORacea®

(doxycycline, USP) *30 mg immediate release &
10 mg delayed release beads
(OR-RAY-SHA)

REACHING FAVORABLE AGREEMENT WITH GALDERMA

Option to Regain Commercialization Rights at No Cost 5 Years following 1st Sale

- \$11 million in upfront and product approval payments
- Mid- to high-teen percentage of royalties on net sales
- Up to additional \$9 million in sales milestone payments
- Option to regain commercialization rights 5 years following first sale at no cost
- Cash-flow positive deal as of launch
- Allows for focus on innovative pipeline



IMPLEMENTING INNOVATION

Enabling Microencapsulation Technology

- Proprietary silica-based microencapsulation technology allows development of drugs that have the potential to be more effective and tolerable than existing drugs
- Core/shell structure designed to boost tolerability
- High encapsulation efficiency aimed to improve stability
- Particle size and release rate tuned to allow efficient delivery of the entrapped API
- Patented platform strengthens our IP and creates barrier to entry for generic drugs



IMPORTANT SAFETY INFORMATION

Indication: TWYNEO® (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. **Adverse Events:** The most common adverse reactions (incidence $\geq 1\%$) in patients treated with TWYNEO Cream were pain (stinging, burning, or pain), dryness, exfoliation, erythema (redness), dermatitis, pruritus (itching) and irritation - all at the application site. **Warnings/Precautions:** Patients using TWYNEO Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of TWYNEO Cream immediately and seek medical attention. Skin irritation may be experienced, including application site dryness, pain (stinging, burning or pain), exfoliation, erythema (redness), dermatitis, pruritus (itching) and irritation. Depending upon the severity, use a moisturizer, reduce the frequency of the application, or discontinue use. Avoid application to cuts, abrasions, eczematous, or sunburned skin. TWYNEO Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of TWYNEO Cream at the first evidence of sunburn. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. **Adverse Events:** The most common adverse reactions (incidence $\geq 1\%$) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. **Warnings/Precautions:** Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

PURSuing LEADERSHIP IN DERMATOLOGY

Innovative Pipeline of Topical Skin Medications



DEVELOPING FIRST ERLOTINIB TOPICAL DRUG

SGT-210 for Keratoderma and other Skin Conditions

Intended to regulate epidermal growth factor receptor (EGFR) without significant side effects caused by the oral drug

20 patent applications for erlotinib in various skin conditions (as of May 12, 2021)

Potential IP protection until 2041

NEXT
STEPS
SGT-210

Initiate clinical development with a higher concentration of erlotinib in H1 23

DEVELOPING NOVEL TAPINAROF CREAM

SGT-310 for Psoriasis and other Skin Conditions

Intended to be an alternative to an FDA approved tapinarof cream, 1%

42 patent applications for tapinarof in various skin conditions (as of May 12, 2021)

Potential IP protection until 2042

NEXT
STEPS
SGT-310

Initiate clinical development in H1 23

DEVELOPING NOVEL ROFLUMILAST COMBINATION TOPICAL DRUG

SGT-510 (Roflumilast + “Agent A”) for Psoriasis and other Skin Conditions

Designed to be potentially more effective than roflumilast cream, 0.3%, for which an NDA was submitted to the FDA

NEXT
STEPS
SGT-510

Initiate clinical development in H2 22

A patent application was filed

Potential IP protection until 2039

FOCUSING ON INNOVATIVE PIPELINE WHILE SECURING NON-DILUTIVE FUNDING

Sale of Generic Assets to Padagis

- Sale of Generic Assets to Padagis in return for \$21 million in quarterly installments over 24 months
- Proceed with 50/50 gross profit-sharing collaboration on 2 programs encompassing 4 high-value generic drug candidates
- Allows for focus on innovative pipeline
- Reduces the need to raise dilutive capital

SECURING A STRONG BALANCE SHEET

Financial Profile

Financials

March 31, 2022

Cash and Investments \$36.3 million

Shares Outstanding 23,119,068 ordinary shares

Expected Partnership Payments Quarterly payments by Padagis; Royalties from Galderma

Cash Runway Based on expected payments from Galderma and Padagis, we anticipate that our cash resources will enable funding of operational and capital expenditure requirements until the end of 2023

Gross proceeds of \$86.3 million raised in IPO on February 5, 2018

Gross proceeds of \$11.5, \$23 and \$5 million raised in follow-on offerings on August, 2019, February 2020, and April 2020, respectively

Generated non-dilutive income totaling \$63.7 million from agreements with Galderma, Padagis and royalties from two generic drugs

\$3.2 million net revenues from generic products in 2021



BUILDING OUR FUTURE

Investor Highlights



- Completed development of EPSOLAY and TWYNEO and gained FDA approvals



- Maximized likelihood of market success for EPSOLAY and TWYNEO through commercialization agreements with US market leader, while retaining the option to regain commercialization rights 5 years following 1st commercial sale



- Defined innovative product pipeline which targets multiple significant US markets and paves the way, together with the market success of EPSOLAY and TWYNEO, to transform Sol-Gel into a leading dermatology company



NASDAQ: SLGL
